Matinas BioPharma Holdings, Inc. MTNB PHARMA
Company Overview
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Why Investors Should Care
Revenue has grown at a 55.7% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.33.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -65.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 55.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 55.71% |
| 1 Year: | -65.62% |
Stock Price Performance
| 1 Year: | -88.33% |
| 6 Months: | -69.87% |
| 3 Months: | -77.80% |
| 1 Month: | -35.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)32.14 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 55.7% over 5 years.
CONS
- Trading 92.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MTNB Matinas BioPharma Holdings, Inc. PHARMA | 0.18 | -0.16 | $2.64M | 0.00% | -121.15% | -141.24% | 55.71% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 89.81K | - | - | - | 95.83K | 33.33K | - | - | - | 1.06M | 1.06M | 1.10M | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | - | -2.13M | -2.42M | -2.61M | -2.57M | -2.40M | -2.16M | -2.24M | -1.62M | -1.84M | -4.49M | -3.98M | -3.41M | -4.12M | -3.40M | -2.95M | -4.10M | -4.52M | -4.56M | -6.35M | -5.77M | -5.60M | -6.35M | -4.79M | -6.88M | -7.72M | -5.92M | -5.46M | -5.59M | -6.16M | -6.13M | -5.90M | -5.84M | -4.38M | -1.95M | -1.84M | -1.58M | -1.94M |
| Net Income | -112.13K | -343.31K | -1.46M | -2.14M | -2.43M | -2.61M | -2.57M | -2.40M | -2.15M | -2.24M | -1.62M | -1.84M | -4.50M | -3.97M | -3.39M | -4.11M | -3.41M | -2.94M | -4.05M | -3.34M | -4.40M | -5.05M | -5.61M | -5.45M | -4.96M | -4.79M | -6.84M | -5.98M | -5.92M | -5.46M | -5.51M | -6.06M | -6.05M | -5.82M | -5.72M | -4.28M | -1.66M | -5.25M | -1.53M | -1.92M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.03 | -0.03 | -0.03 | -0.03 | -1.39 | -1.34 | -1.15 | -0.85 | -0.33 | -1.03 | -0.40 | -0.30 |
| R&D Expense | 49.59K | 240.11K | 745.00K | 1.07M | 1.12M | 1.07M | 1.45M | 1.35M | 879.20K | 921.71K | 642.58K | 835.31K | 2.38M | 2.31M | 2.01M | 2.19M | 1.52M | 1.38M | 2.31M | 2.83M | 2.67M | 4.09M | 3.41M | 3.34M | 3.24M | 2.48M | 4.62M | 4.98M | 4.13M | 3.71M | 3.97M | 3.56M | 3.29M | 3.45M | 3.37M | 2.24M | 85.00K | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 194.49K | 0 | 149.69K | 119.75K | 89.81K | 158.33K | 33.00K | 3.19M | 1.10M | - | - |
| Operating Income | -3.71M | -10.46M | -9.91M | -8.26M | -16.50M | -14.65M | -18.92M | -24.21M | -24.73M | -24.59M | -23.77M | -24.59M | -6.96M |
| Net Income | -3.71M | -10.22M | -9.14M | -7.60M | -15.49M | -14.08M | -17.37M | -22.45M | -23.28M | -21.00M | -22.94M | -24.25M | -10.35M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.10 | -5.28 | -4.98 | -2.00 |
| R&D Expense | 1.76M | 5.18M | 5.29M | 3.95M | 9.01M | 6.79M | 11.23M | 14.36M | 14.58M | 16.68M | 14.49M | 11.43M | 85.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 11.33M | 3.36M | 8.41M | 9.82M | 14.42M | 19.94M | 40.24M | 70.97M | 61.33M | 44.82M | 25.10M | 12.64M | 7.21M |
| Total Equity | -116.59K | 10.47M | 2.23M | 6.07M | 7.15M | 10.68M | 16.14M | 33.05M | 63.73M | 52.49M | 36.64M | 19.25M | 7.59M | 4.83M |
| Cash & Equivalents | 424.36K | 10.84M | 2.59M | 3.23M | 4.11M | 7.31M | 12.45M | 22.17M | 12.43M | 21.03M | 6.83M | 4.79M | 7.28M | 4.00M |
| Total Liabilities | - | 858.97K | 1.13M | 2.33M | 2.67M | 3.74M | 3.80M | 7.19M | 7.24M | 8.83M | 8.18M | 5.86M | 5.05M | 2.38M |
| Current Liabilities | - | 858.97K | 1.12M | 1.13M | 1.44M | 1.77M | 2.84M | 3.10M | 3.57M | 4.35M | 4.29M | 2.62M | 2.67M | 1.46M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -7.81M | -6.12M | -11.46M | -10.32M | -14.09M | -17.37M | -15.22M | -19.16M | -15.28M | -15.88M | -7.01M |
| Investing Cash Flow | - | - | -5.42K | - | -942.18K | -535.92K | -6.01M | -40.67M | 16.77M | 4.88M | 13.24M | 9.21M | 335.00K |
| Financing Cash Flow | - | - | 8.46M | 7.00M | 15.60M | 15.87M | 29.85M | 48.05M | 6.96M | 79.00K | -7.00K | 9.17M | 3.39M |
| Capital Expenditure | -94.19K | -288.52K | -76.18K | -0 | -942.18K | -535.92K | -405.60K | -5.75K | -260.00K | -892.00K | -218.00K | - | - |
| Free Cash Flow | - | - | -7.89M | -6.12M | -12.40M | -10.86M | -14.50M | -17.37M | -15.48M | -20.05M | -15.50M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -5,096.0% | - | -11,024.6% | -12,230.9% | -21,067.4% | -15,288.4% | -74,954.5% | -771.3% | -2,168.4% | - | - |
| Net Margin % | - | - | -4,697.0% | - | -10,345.9% | -11,760.4% | -19,343.4% | -14,177.0% | -70,554.5% | -658.6% | -2,093.2% | - | - |
| ROE % | -35.4% | -458.8% | -150.4% | -106.3% | -145.0% | -87.2% | -52.6% | -35.2% | -44.4% | -57.3% | -119.2% | -319.5% | -214.2% |
| ROCE % | -35.4% | -466.5% | -136.2% | -98.6% | -130.4% | -85.6% | -50.9% | -35.9% | -43.4% | -60.7% | -105.7% | -246.5% | -121.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Renaissance Technologies, LLC | 0.48% | 71.04K | $11.39K |
| 2 | Blackrock Inc. | 0.34% | 50.26K | $8.06K |
| 3 | Geode Capital Management, LLC | 0.33% | 49.13K | $7.88K |
| 4 | Vanguard Capital Management LLC | 0.27% | 40.11K | $6.43K |
| 5 | Holos Integrated Wealth LLC | 0.22% | 32.48K | $5.21K |
| 6 | Vanguard Fiduciary Trust Co | 0.12% | 17.32K | $2.78K |
| 7 | Susquehanna International Group, LLP | 0.11% | 16.09K | $2.58K |
| 8 | Citadel Advisors Llc | 0.11% | 15.46K | $2.48K |
| 9 | State Street Corporation | 0.10% | 15.32K | $2.46K |
| 10 | Sargent Investment Group, LLC | 0.09% | 12.72K | $2.04K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MTNB
Biotech Matinas pivots into green hydrogen as GH Power goes public in NYSE deal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOV201SE9zRXRNX2Y0RjhEWkRSaVd1RnZqUTZKRUx6VEJTV3NVRTVCZmd0OHFxZl9PbVRoMURGbWFSVDVxbEk5MHlpWnRMMG9GbVRJdkk1clN3ZkVENHllMlROSHZOY3pMYTBDRF9xT3ZXNjJsTjlCN2NNNk1VbDFiUTF4OGFpQjNIa2M3dU…
Matinas BioPharma Receives NYSE American Noncompliance Notice for Continued Listing Standards - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOVkZLWU00OG0wREVXekh5MGJEeFdweHBidHkzajB3Zk03UWkyTEZlZXdVeFhyZTVlenBZZi03LWQyLVFTVkFiSG9jS1VrUmZQQ3FpbzZIeXI0bllrRF8zeV9xY3lmVkJCdXV3bXVCaWt6V2VoQk5tSTA5SUZxNFctMS1ONWhSVHZZWEllSm…
MTNB - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5YVUNUS2tXaHpCTXpMLUZ2NC04RWxNeElpTklmWld5MVVpMUlwVjY3YzMwVjB1ZjNqcTFxWTczSDk2blhia2c?oc=5" target="_blank">MTNB</a> <font color="#6f6f6f">Finviz</font>…
MTNB|Matinas BioPharma Holdings Inc|Price:0.183|Chg%:-0.058 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5fWjd4NnBPX193QXhydFBmSUtyMmZERUZ4TGxOLURaWkRRNXZTNzJGa2lHS25kZG9ITEdQWDdycGFrNWJxTGtqOWxQd2I1SjFwV3VRU0xIRVY0QzdDZWZtZmVOUTBFaEt5WTJObFVR?oc=5" target="_blank">MTNB|Matinas BioPha…
Which stocks have an unusual volume on Wednesday? - ChartMill
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQZGlrdHBxX2YzN1dhbXo5dTZ1enpCaHBQTkJHVUk3MURjYmtDSHkwVElyT2QwdzRseEFHSkhoU01wcUhBVkNvdTRocG9MWXFQMnotSy1oUE1CNW92dUQ0ZUU3aVp1RjU0SUphckttRmtnQXdpR0FVUXd1TTlBZzRlZDJYUDRCeUtLcHMwbT…
Trending Stocks Today | Matinas BioPharma Surges 44.65% Post-Market - Moomoo
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTkJYZllCOHduZ2JqdWZsZ294WlF5WUp6ald4Uk5uQlFCRnlBVEhjRjdSak5DSXRDcXpoV00tSTlCc3FQakVrQ3k3VTFGdTJlOERNNWtjNndubkFHVjFrUGUtajNPT1hEbncxcm8yM1NUTU8yeGJyRG9xRDZFSEk3N0I2eHEta29uUWx6eV…
MTNB — Frequently Asked Questions
What is the current share price of Matinas BioPharma Holdings, Inc. (MTNB)?
As of 2026-09-19 21:16 PDT, Matinas BioPharma Holdings, Inc. (MTNB) trades at $0.18 on NYSE American. Its 52-week range is $0.18 to $2.36.
What is the market capitalisation of MTNB?
Matinas BioPharma Holdings, Inc. (MTNB) has a market capitalisation of $2.64M on NYSE American.
What is the P/E ratio of MTNB?
MTNB trades at a trailing price-to-earnings (P/E) ratio of -0.16. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.57.
What is the return on equity (ROE) of MTNB?
MTNB has a return on equity (ROE) of -141.24%. Its return on capital employed (ROCE) is -121.15%.
Is MTNB a good stock to buy?
This page provides a data-driven analysis of Matinas BioPharma Holdings, Inc. (MTNB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.